Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · USM201561018 US Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2020-12-21 Regulatory Filings
Country US United States of America
Listing US ENLV

About Enlivex Therapeutics Ltd.

https://www.enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release about the publication of clinical trial data and does not contain comprehensive financial statements or detailed financial analysis. The document length is short (2154 characters), and it primarily serves as a regulatory announcement rather than a full report. It references a press release as an exhibit, indicating it is an announcement rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-12-21 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release about the issuance of a new Chinese patent. The document is short (2004 characters) and primarily serves as a regulatory announcement rather than a full report. It does not contain detailed financial statements or substantive financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-12-07 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Enlivex Therapeutics Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It announces a press release about positive interim results from a Phase II clinical trial. The document is short (1967 characters) and primarily serves to furnish a press release as an exhibit. There are no detailed financial statements or substantive financial data presented. This type of filing is a regulatory announcement of information rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and press release filing.
2020-12-03 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It contains a press release about a clinical outcome and does not include detailed financial statements or comprehensive financial analysis. The document length is short (2129 characters) and it primarily announces a press release rather than providing a full report. According to the rules, such filings that are announcements or press releases submitted on Form 6-K are best classified as Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-11-18 English
REPORT OF FOREIGN PRIVATE ISSUER
Board/Management Information Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, Enlivex Therapeutics Ltd., reporting the appointment of a new board member, Dr. Brian Schwartz. It details the director appointment, compensation arrangements, and related transactions. The document does not contain financial statements or quarterly results but focuses on management/board changes. The Form 6-K is used for current reports by foreign private issuers and this filing specifically announces a change in the company's board of directors. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 3337 characters, which is consistent with a brief announcement rather than a full report or earnings release.
2020-11-17 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Enlivex Therapeutics Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content includes a press release announcement about a presentation at a conference and does not contain detailed financial statements or substantive financial data. The document length is 2092 characters, which is relatively short and primarily serves as a notification of an event and includes a press release as an exhibit. According to the rules, such filings that announce events or provide press releases without detailed financial data or full reports are classified as Regulatory Filings (RNS).
2020-11-12 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.